Genistein, VRT-532, and UCCF-152 are organic, small molecules (<800 Da) that alter the activity of the CFTR channel protein by either direct effects (eg, potentiation—increasing channel open time) or activation of cell signaling pathways (eg, adenylyl cyclase and intracellular Ca2+).
Wild-type HSNE cells grown on Transwell permeable supports were mounted in modified Ussing chambers under short-circuit conditions and sequentially exposed to amiloride (100µM), modulators, forskolin (100nM), and CFTRINH-172 (10µM). By convention, a positive deflection in the tracing (ΔISC) represents movement of an anion (ie, Cl−) in the serosal to mucosal direction. DMSO, dimethyl sulfoxide.
Genistein was a more robust activator of CFTR-mediated anion transport in the absence of forskolin (A) than the potentiators VRT-532 and UCCF-152 (Tukey-Kramer P < .05). Cl− transport (measured by short-circuit current [∆ISC]) was significantly greater for each modulator compared with dimethyl sulfoxide vehicle control (Tukey-Kramer P < .05). However, total activation of CFTR (plus forskolin 100nM) was similar between drugs (B). All agonists significantly increased total CFTR-mediated transport compared with forskolin alone (Tukey-Kramer P < .05).
Potentiators were administered apically to wild-type (A) or F508del/F508del (B) human sinonasal epithelium for 15 minutes. Genistein and UCCF-152 increased CBF compared with baseline, and CBF was significantly greater than in cells treated with dimethyl sulfoxide vehicle control (Tukey-Kramer P < .05) in wild-type HSNE. Ciliary beat frequency was not significantly increased with VRT-532 despite significantly greater stimulation of Cl− secretion when compared with UCCF-152. Activation of CBF was diminished in cells that lack functional CFTR, but genistein significantly increased CBF compared with controls (Tukey-Kramer P < .05).
Conger BT, Zhang S, Skinner D, Hicks SB, Sorscher EJ, Rowe SM, Woodworth BA. Comparison of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Ciliary Beat Frequency Activation by the CFTR Modulators Genistein, VRT-532, and UCCF-152 in Primary Sinonasal Epithelial Cultures. JAMA Otolaryngol Head Neck Surg. 2013;139(8):822-827. doi:10.1001/jamaoto.2013.3917
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Pharmacologic activation of mucociliary clearance (MCC) represents an emerging therapeutic strategy for patients with chronic rhinosinusitis, even in the absence of congenital mutations of the CFTR gene. Drug discovery efforts have identified small molecules that activate the cystic fibrosis transmembrane conductance regulator (CFTR), including potentiators under development for treatment of cystic fibrosis.
To evaluate the properties of CFTR modulators and their effects on ciliary beat frequency (CBF) in human sinonasal epithelium (HSNE).
Primary HSNE cultures (wild type and F508del/F508del) were used to compare stimulation of CFTR-mediated Cl− conductance and CBF by the CFTR modulators genistein, VRT-532, and UCCF-152.
Main Outcomes and Measures
Increase in CFTR-dependent anion transport and CBF.
HSNE cultures were analyzed using pharmacologic manipulation of ion transport (change in short-circuit current [∆ISC]) and high-speed digital imaging (CBF). Activation of CFTR-dependent anion transport was significantly different among agonists (P < .001), with genistein exerting the greatest effect (mean [SD] ∆ISC, genistein, 23.1 [1.8] μA/cm2 > VRT-532, 8.1 [1.0] μA/cm2 > UCCF-152, 3.4 [1.4] μA/cm2 > control, 0.7 [0.2] μA/cm2; Tukey-Kramer P < .05) in the absence of forskolin. Genistein and UCCF-152 augmented CBF (under submerged conditions) significantly better (Tukey-Kramer P < .05) than cells treated with VRT-532 or dimethyl sulfoxide vehicle control (mean [SD] fold change over baseline, genistein, 1.63 [0.06]; UCCF-152, 1.56 [0.06]; VRT-532, 1.38 [0.08]; control, 1.27 [0.02]). Activation of CBF was blunted in F508del/F508del HSNE cultures.
Conclusions and Relevance
The degree of CBF stimulation was not dependent on the magnitude of Cl− secretion, suggesting that different mechanisms of action may underlie MCC activation by these small molecule potentiators. Agents that activate both CFTR-dependent ISC and CBF are particularly attractive as therapeutics because they may address 2 independent pathways that contribute to deficient MCC in chronic rhinosinusitis.
Functional sinonasal respiratory epithelium plays a critical role in the prevention of chronic rhinosinusitis. Inflammation of sinonasal respiratory epithelium and decreased mucociliary clearance (MCC) predispose patients to upper and lower respiratory bacterial infections and chronic sinus disease.1 Physiologic MCC is dependent on many factors, including ciliary beat frequency (CBF) and the depth and composition of airway surface liquid (ASL), together with constituents of the mucus and its physical properties.
The ASL depth and composition is regulated by vectorial ion transport of ions, such as chloride (Cl−) and bicarbonate (HCO3−).2- 7 Diminished Cl− and HCO3− transport through the cystic fibrosis transmembrane conductance regulator (CFTR) is thought to increase mucus viscosity and dehydrate ASL, leading to stasis and impairment of MCC. A genetic absence or dysfunction of CFTR (the major apical anion transporter in respiratory epithelia) results in the disease cystic fibrosis (CF). Patients with CF develop thick, dehydrated mucus, resulting in widespread chronic pansinusitis.8
Pharmacologic compounds known to stimulate CFTR enhance Cl− secretion in vitro and in vivo9- 14 and have been the subject of a number of research programs directed toward treatment of MCC-related diseases such as CF and chronic obstructive pulmonary disease.15 Prior studies by our laboratory have demonstrated that flavonoids and related compounds enhance Cl− secretion in human sinonasal epithelium (HSNE).9,10,12 The isoflavone genistein was shown to potentiate CFTR opening and to increase transepithelial Cl− transport in HSNE.16 The molecule is well studied and has an excellent safety profile.17,18 In 2006, Vertex Pharmaceuticals used high-throughput screening to identify 4-methyl-2-(5-phenyl-1H-pyrazol-3-yl)phenol, or VRT-532, as a robust potentiator of wild-type CFTR (OMIM 602421), as well as CFTR encoding the common F508del mutation.19 In addition, the isoxazole UCCF-152 [3-(2-benzyloxy-phenyl)-5-chloromethyl-isoxazole] was identified as an activator of CFTR-mediated anion secretion.20 The chemical structures of these small molecules are shown in Figure 1. Because the magnitude of Cl− transport is related to both ASL hydration and ciliary beating,21 the strength of Cl− channel activation specific to human CFTR measured in primary HSNE in vitro may provide a useful means of selecting and optimizing agents worthy of additional clinical study.
The present experiments were designed to assess the relative activation of CFTR-mediated Cl− transport and ciliary activity by the modulators genistein, VRT-532, and UCCF-152 in primary HSNE and to guide selection of potential therapeutics directly delivered to the sinus epithelium.
Institutional review board approval was obtained prior to the initiation of this study.
The technique of culturing HSNE at an air-liquid interface has been described previously.22- 26 In brief, HSNE was obtained from nasal epithelial tissue removed during endoscopic sinus and skull base surgical procedures. Tissue was also harvested from 1 individual with CF (F508del/F508del) to evaluate CFTR dependence of the agonists. Tissue was grown on Costar 6.5-mm-diameter permeable filter supports (Corning Life Sciences) submerged in culture medium. The medium was removed from the monolayer surface on day 4 after reaching confluence. The cells were then fed via the basal chamber. Differentiation and ciliogenesis occurred in all cultures by 10 to 14 days.
Solutions and chemicals. The bath solution contained 120mM NaCl, 25mM NaHCO3, 3.3mM KH2PO4, 0.8mM K2HPO4, 1.2mM MgCl2, 1.2mM CaCl2, and 10mM glucose. The pH of this solution is 7.3 to 7.4 when gassed with a mixture of 95% O2 and 5% CO2 at 37°C. Chemicals were obtained from Sigma. The UCCF-152 and VRT-532 were supplied by R. Bridges, PhD (Rosalind Franklin University of Medicine and Science), and Cystic Fibrosis Foundation Therapeutics. Each solution was generated as 1000 × stock and used at 1 × in the Ussing chamber or for CBF analysis. All Ussing chamber experiments were performed with low Cl− concentration (6mM) in the mucosal bath. Pharmacologic working concentrations were as follows: amiloride, 100μM; forskolin, 100nM; genistein, 50μM; VRT-532, 10μM; UCCF-152, 50μM; and CFTRINH-172, 10μM. Optimal working concentrations of genistein, VRT-532, and UCCF-152 were determined after careful dose-response evaluation of CFTR activation in Ussing chambers. All stock solutions were dissolved in a dimethyl sulfoxide (DMSO) vehicle. Amiloride was used to block epithelial Na+ channel activity, ensuring that changes in short-circuit current (ΔISC) during subsequent manipulation were secondary to effects on Cl− transport. Forskolin activates CFTR via a cyclic adenosine monophosphate (cAMP)-dependent mechanism. INH-172 is a specific inhibitor5 of CFTR that allowed the relative contribution of CFTR (vs other anion transport pathways) to be determined in Ussing chamber systems.
Short-circuit (ISC) measurements. Transwell inserts (Costar) were mounted in vertical Ussing chambers and continuously short-circuited after fluid resistance compensation using automatic voltage clamps (VCC 600; Physiologic Instruments). Inserts were tested in bath solutions warmed to 37°C and continuously gas-lifted with a 95% O2 /5% CO2 mixture. The ISC was measured at 1 sample per second. By convention, a positive deflection in ISC is defined as the net movement of anions in the serosal-to-mucosal direction.
Images were visualized using a 20× objective lens on an inverted microscope (Fisher Scientific). Data were captured using a model A602f-2 Basler area scan high-speed monochromatic digital video camera (Basler AG) at a sampling rate of 100 frames per second and a resolution of 640 × 480 pixels. Video images were analyzed using the Sisson-Ammons Video Analysis (SAVA) system, version 2.1.6. For each experiment, a large area of beating cilia on air-liquid interface cultures was identified with the inverted microscope and the digital image signal was routed from the camera directly into an acquisition board (National Instruments) within a Dell Workstation running the Windows XP Professional operating system. Images were analyzed with virtual instrumentation software for CBF analysis. All recordings were made at original magnification ×200 .
Experiments were performed at ambient temperature (23°C). A baseline recording of CBF was conducted for each cell monolayer prior to apical administration of test solution because apical fluid addition, by itself, can increase CBF. Additional fluid depth overlying the respiratory epithelial cell surface stimulates CBF as a result of improved hydration and optimal fluid dynamics. Thus, all experiments compared the effects of agonists to that of a DMSO vehicle control solution. Whole field analysis was conducted with each point measured representing 1 cilium. The reported frequencies describe arithmetic means of these values, followed by standard deviations. Each analysis was normalized to fold-change over baseline.
Statistical analyses were performed using analysis of variance followed by post hoc evaluation with the Tukey-Kramer method for multiple comparisons. All statistical tests were assessed at a 5% significance level (ie, α = .05).
A total of 70 primary HSNE (harvested from 3 individuals) and 24 F508del/F508del HSNE cultures were used in the completion of these studies. Only cultures with transepithelial resistance (Rt) of greater than 500 Ω cm2 and ciliary differentiation were evaluated in Ussing chambers and stimulated for CBF analysis. A minimum of 5 wells were used per condition.
CFTR-mediated anion transport (mean [SD] change in short-circuit current [∆ISC]) was measured using HSNE cultures in Ussing chambers (Figure 2). Activation of transepithelial Cl− transport to significantly different degrees was noted among agents (n ≥ 7 per condition; genistein, 23.1 [1.8] μA/cm2 > VRT-532, 8.1 [1.0] μA/cm2 > UCCF-152, 3.4 [1.4] μA/cm2 > control, 0.7 [0.2] μA/cm2; analysis of variance P < .001; Tukey-Kramer P < .05) (Figure 3A). Importantly, supplementary stimulation of CFTR was measured by means of addition of forskolin and was similar among the 3 modulator groups (genistein, 32.1 [2.9] μA/cm2; VRT-532, 32.1 [2.4] μA/cm2; UCCF-152, 29.2 [4.0] μA/cm2), suggesting that each agent is additive to forskolin and that anion transport phenotypes were similar among cultured HSNE cells (Figure 3B). Stimulation of anion transport was significantly greater with agonist + forskolin vs DMSO control vehicle + forskolin (19.7 [0.6] μA/cm2; Tukey-Kramer P < .05). None of the 3 drugs tested activated CFTR-dependent Cl− secretion in F508del/F508del HSNE (data not shown), indicating that stimulation of anion transport is completely dependent on the presence of functional CFTR.
Genistein and UCCF-152 robustly stimulated CBF (mean [SD] fold change over baseline, genistein, 1.63 [0.06]; UCCF-152, 1.56 [0.06]) under submerged conditions when compared with DMSO control (1.27 [0.02]; Tukey-Kramer P < .05) (Figure 4A). In contrast, only mild stimulation of CBF was noted with the addition of VRT-532 (mean [SD] fold change, 1.38 [0.08]) that was not significantly different from controls. This suggests minimal direct effects of the agent on the ciliary beat apparatus. Activation of CBF was diminished in F508del/F508del HSNE, signifying that the presence of functional CFTR is crucial to overall effects on mucociliary transport (Figure 4B). However, despite abrogated stimulation with the addition of the 3 drugs, genistein significantly augmented CBF when compared with DMSO control (Tukey-Kramer P < .05).
Flavonoids and isoflavonoids make up a group of secondary plant metabolites derived from the common flavones 2-phenyl-1,4-benzopyrone and 3-phenyl-1,4-benzopyrone. In recent years, many of these compounds have been studied for their potential beneficial effects on health, including their antioxidant properties and anticancer activity. Genistein is an isoflavonoid that has also been identified as a robust activator of in vivo CFTR Cl− conductance in human airway epithelial cells.16,27 Furthermore, some flavonoids, such as quercetin and hesperidin, strongly activate CFTR-mediated anion transport in HSNE.28 These agents amplify the frequency and duration of phosphorylated CFTR Cl− channel openings, leading to increased luminal Cl− concentration.29,30 In addition, drug discovery efforts using high-throughput screening techniques have identified novel small molecules that activate CFTR. VRT-532 and UCCF-152 are 2 such compounds that stimulate CFTR-mediated anion transport and have been proposed as potential CF therapeutics.19,20 VRT-532 potentiates CFTR by augmenting cAMP-dependent regulation of the Cl− channel.19 Subsequent investigations have indicated that UCCF-152 activates CFTR by inducing protein kinase A–dependent phosphorylation of the regulatory domain of CFTR.20
In the present study, we evaluated the in vitro effects of genistein, VRT-532, and UCCF-152 on CFTR-mediated Cl− conductance and CBF in primary cultures of HSNE. Our findings indicate that, among the 3 modulators, genistein is the most robust activator of human CFTR. We also established that genistein and UCCF-152 stimulate CBF—a finding that, to our knowledge, has not previously been reported. Whereas anion transport varied across 3 different CFTR modulators, the degree of CBF stimulation did not correlate with magnitude of Cl− secretion. Interestingly, VRT-532 did not demonstrate activation of CBF despite much stronger stimulation of Cl− transport compared with UCCF-152. Activation of cAMP-dependent pathways by UCCF-152 is likely responsible for the prominent increase in ciliary beating, on the basis of the observation that CBF is activated, in part, by this cell signaling pathway. Whereas increases in cytosolic Ca2+ concentration through both mechanical (eg, membrane stretch) and paracrine (eg, adenosine triphosphate and uridine triphosphate) mechanisms are also critical factors regulating the velocity of mucociliary transport,4 the lack of Ca2+-activated Cl− channel stimulation in F508del/F508del CF HSNE (data not shown) Ussing chamber tracings indicates that this signaling pathway does not contribute to the measured effects. Abrogation of CBF stimulation in F508del/F508del HSNE demonstrates that the majority of effects are likely attributable to CFTR-dependent fluid secretion and thus illustrates the importance of functional CFTR to the mucociliary apparatus. The composition and/or viscosity of mucus have been suggested to depend on CFTR anion secretion, and robust anion secretion might act in part to augment CBF by altering the physical properties of periciliary mucus. However, genistein significantly increased CBF in the absence of CFTR despite the inability to trigger signaling pathways known to stimulate CBF (cAMP-dependent or Ca2+ signaling). Thus, additional studies will be required to establish the means by which genistein activates CBF.
Genistein robustly stimulates transepithelial Cl− transport and CBF in primary cultured HSNE, indicating pronounced activity in a model system highly relevant to chronic rhinosinusitis. Other agents tested also promoted CFTR-dependent Cl− secretion but did not necessarily increase CBF, indicating alternative mechanisms of action. These studies establish a basis for clinical testing of CFTR activators on markers of sinonasal MCC, in particular agents that activate both CBF and anion transport through a variety of cell signaling pathways. Our data support the use of genistein and other CFTR modulators as potential therapeutics for diseases of dysfunctional MCC, including non-CF chronic sinus disease.
Corresponding Author: Bradford A. Woodworth, MD, 563, 1530 3rd Ave, S, Birmingham, AL 35294 (email@example.com).
Submitted for Publication: March 5, 2013; final revision received April 15, 2013; accepted May 14, 2013.
Author Contributions: Drs Conger and Zhang, Messrs Skinner and Hicks, and Drs Rowe and Woodworth had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Sorscher, Rowe, Woodworth.
Acquisition of data: Zhang, Skinner, Hicks, Woodworth.
Analysis and interpretation of data: Conger, Zhang, Skinner, Sorscher, Rowe, Woodworth.
Drafting of the manuscript: Conger, Skinner, Sorscher.
Critical revision of the manuscript for important intellectual content: Conger, Zhang, Hicks, Sorscher, Rowe, Woodworth.
Statistical analysis: Zhang, Skinner, Hicks, Woodworth.
Obtained funding: Sorscher, Woodworth.
Administrative, technical, or material support: Conger, Zhang, Sorscher, Rowe, Woodworth.
Study supervision: Sorscher, Woodworth.
Conflict of Interest Disclosures: Dr Woodworth is a consultant for ArthroCare ENT, Olympus, and Cook Medical. Drs Woodworth, Sorscher, and Rowe are inventors on a patent pending regarding the use of chloride secretagogues for therapy of sinus disease (35 U.S.C. n111(b) and 37 C.F.R n.53 (c)) in the United States Patent and Trademark Office.
Funding/Support: This research was funded by grants from the Flight Attendant Medical Research Institute Young Clinical Scientist Award (072218) and National Institutes of Health/National Heart, Lung, and Blood Institute (1K08HL107142-03) to B. A. W. and by grants from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (5P30DK072482-03) to E. J. S. and (R01HL105487-01 and 1R03DK084110-01) to S. M. R.
Previous Presentation: This study was presented at the Triological Society Combined Sectional Meeting; January 27, 2012; Miami, Florida.
Correction: This article was corrected August 28, 2013, for an error in the OMIM gene database number.